World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
49
Citations
9826
World Ranking
4327
National Ranking
287

Overview

Sebastian Kobold is affiliated with Ludwig-Maximilians-Universität München in Germany. Their research primarily spans the fields of Medicine and Immunology and Microbiology, with a strong emphasis on several subfields including Oncology, Immunology, Molecular Biology, Biomedical Engineering, and Genetics.

The main topics covered in their work include:

  • CAR-T cell therapy research
  • Immune Cell Function and Interaction
  • Immunotherapy and Immune Responses
  • Cancer Immunotherapy and Biomarkers
  • Nanowire Synthesis and Applications
  • Monoclonal and Polyclonal Antibodies Research
  • Virus-based gene therapy research

Sebastian Kobold has collaborated frequently with several researchers, including:

  • Adrian Gottschlich (36 joint publications)
  • Stefan Endres (33 joint publications)
  • Florian Märkl (23 joint publications)
  • Sophia Stock (22 joint publications)
  • Marion Subklewe (20 joint publications)

Their publications are present in multiple venues, with a notable number of papers featured in:

  • Blood (12 publications)
  • Poster presentations (11 publications)
  • Frontiers in Immunology (8 publications)
  • Journal for ImmunoTherapy of Cancer (8 publications)
  • Cancer Research (6 publications)

Recent papers authored or co-authored by Sebastian Kobold include:

  • Interleukins in cancer: from biology to therapy (2021, Nature reviews. Cancer)
  • CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment (2021, Cell)
  • Melanoma models for the next generation of therapies (2021, Cancer Cell)
  • Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1α-mediated glycolytic reprogramming (2023, Nature Communications)
  • A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers (2023, Science)

Best Publications

  • Interleukins in cancer: from biology to therapy.

    Daria Briukhovetska;Janina Dörr;Stefan Endres;Peter Libby

  • Advances in cancer immunotherapy 2019 – latest trends

    Stephan Kruger;Stephan Kruger;Matthias Ilmer;Matthias Ilmer;Sebastian Kobold;Bruno L. Cadilha

  • Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells

    Mohamed Reda Benmebarek;Clara Helke Karches;Bruno Loureiro Cadilha;Stefanie Lesch

  • Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity.

    Lucas Ferrari de Andrade;Rong En Tay;Deng Pan;Adrienne M. Luoma

  • Teaching an old dog new tricks: next-generation CAR T cells

    Nicholas Tokarew;Justyna Ogonek;Stefan Endres;Michael von Bergwelt-Baildon

  • CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment.

    Mauro Di Pilato;Mauro Di Pilato;Raphael Kfuri-Rubens;Raphael Kfuri-Rubens;Jasper N. Pruessmann;Aleksandra J. Ozga

  • Melanoma models for the next generation of therapies

    E. Elizabeth Patton;Kristen L. Mueller;David J. Adams;Niroshana Anandasabapathy

  • Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis

    Xiao Liu;Junjian Li;Bruno Loureiro Cadilha;Anamarija Markota

  • Inflammation: a common contributor to cancer, aging, and cardiovascular diseases-expanding the concept of cardio-oncology.

    Peter Libby;Sebastian Kobold

  • RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells.

    P Duewell;A Steger;H Lohr;H Bourhis

  • Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy

    Stefan Stoiber;Bruno L. Cadilha;Mohamed-Reda Benmebarek;Stefanie Lesch

  • A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers

    Unknown

  • Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.

    Dana Stenger;Tanja A. Stief;Theresa Kaeuferle;Semjon Willier

  • T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours

    Stefanie Lesch;Viktoria Blumenberg;Stefan Stoiber;Adrian Gottschlich

  • Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models.

    Marcel André Schneider;Laura Heeb;Michal Mateusz Beffinger;Stanislav Pantelyushin

  • Enhancing tumor T cell infiltration to enable cancer immunotherapy.

    Jin Zhang;Stefan Endres;Sebastian Kobold

  • Toll-Like Receptor 4–Induced IL-22 Accelerates Kidney Regeneration

    Onkar P. Kulkarni;Ingo Hartter;Shrikant R. Mulay;Jan Hagemann

  • Impact of a New Fusion Receptor on PD-1–Mediated Immunosuppression in Adoptive T Cell Therapy

    Sebastian Kobold;Simon Grassmann;Michael Chaloupka;Christopher Lampert

  • Utilizing chemokines in cancer immunotherapy

    Unknown

  • Cancer cells induce interleukin-22 production from memory CD4 + T cells via interleukin-1 to promote tumor growth

    Cornelia Voigt;Peter May;Adrian Gottschlich;Anamarija Markota

  • Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.

    Monika Herrmann;Christina Krupka;Katrin Deiser;Bettina Brauchle

  • Modes of action of TLR7 agonists in cancer therapy.

    Sebastian Kobold;Gabriela Wiedemann;Simon Rothenfußer;Stefan Endres

  • Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy.

    Sebastian Kobold;Stanislav Pantelyushin;Felicitas Rataj;Johannes vom Berg

Frequent Co-Authors

Stefan Endres
Stefan Endres Ludwig-Maximilians-Universität München
Christian Klein
Christian Klein Roche (Switzerland)
Karl-Peter Hopfner
Karl-Peter Hopfner Ludwig-Maximilians-Universität München
Nicolaus Kröger
Nicolaus Kröger Universität Hamburg
Volker Heinemann
Volker Heinemann Ludwig-Maximilians-Universität München
Carsten Bokemeyer
Carsten Bokemeyer Universität Hamburg
Pablo Umana
Pablo Umana California Institute of Technology
Friedrich Haag
Friedrich Haag Universität Hamburg
Klaus-Peter Janssen
Klaus-Peter Janssen Technical University of Munich
Thomas Clavel
Thomas Clavel RWTH Aachen University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring complementary healthcare fields can broaden career opportunities. Many students pursue accelerated nursing paths that build foundational knowledge applicable to immunological research and patient care. Programs like accelerated np programs online offer a fast track into advanced nursing roles, ideal for professionals seeking to integrate clinical expertise with immunology.

Even individuals without prior healthcare experience can transition into nursing through options such as the best online rn programs for non nurses. These programs provide foundational training that aligns well with immunology’s focus on human health and disease.

If you're looking for more accessible entry points, consider the easiest absn program to get into, which helps streamline the Bachelor of Science in Nursing, a solid stepping stone toward immunology-related healthcare roles.

For those seeking quicker credentials, exploring which lpn programs are easiest to get into can provide essential practical experience. Licensed Practical Nurses gain critical exposure to patient care that supports further study or employment in immunology-focused environments.

Best Scientists Citing Sebastian Kobold

Trending Scientists

Recently Published Articles